Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CELZ creating relationships with satisfied customers.
Human pre-valvular endocardial cells derived from pluripotent stem cells recapitulate cardiac pathophysiological valvulogenesis
https://www.nature.com/articles/s41467-019-09459-5
Another strong day.. $AXSM 16.75
Read the Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with CLSK dated 9/12/18. The agreement calls for $10,000 in cash, and 30,000 restricted 144 shares of CLSK per month. Regal and CLSK have signed an amendment to extend the contract for twelve months starting 10/10/18, and increased the cash component to $20,000 per month. CLSK has paid an additional $12,000 for services provided in November. CLSK has paid an additional $88,000 for services provided in December. CLSK has paid an additional $100,000 for services for January. CLSK has paid an additional $100,000 for services for February. Regal was paid an additional $100,000 for March services. CLSK has paid an additional $100,000 for services for March. CLSK has paid an additional $80,000 for services for April. CLSK has paid All payments were made directly by Clean Spark, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. CLSK was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
https://ih.advfn.com/stock-market/USOTC/cleanspark-inc-CLSK/stock-news/79758122/cleantech-opportunities-you-cant-miss
$BTCY is scheduled to release their next quarterly earnings announcement on Wednesday, June 12th 2019.
https://www.marketbeat.com/stocks/OTCMKTS/BTCY/
Characterizing Mesenchymal Stem Cells
https://www.news-medical.net/whitepaper/20190425/Characterizing-Mesenchymal-Stem-Cells.aspx
Stem Cell Therapy Revolutionizing Conventional Therapy Market
https://www.medgadget.com/2019/04/stem-cell-therapy-revolutionizing-conventional-therapy-market.html
Cleantech Opportunities You Can’t Miss
April 24, 2019 -- InvestorsHub NewsWire -- Microcap Speculators -- Today we are highlighting several clean energy plays that could make you some serious coin.
The first on our list is CleanSpark, Inc. (USOTC: CLSK). It is a microgrid company with several revenue generating projects. It released an Edgar filing reporting $20 million in financing in the form of Debenture, the Series B Preferred Stock, the Warrant and the Common Stock. With the warrants being priced $3.50 per share with respect to 2,000,000 Warrant Shares, $4.00 with respect to 100,000 Warrant Shares, $5.00 with respect to 100,000 Warrant Shares, $7.50 with respect to 50,000 Warrant Shares and $10.00 with respect to 50,000 Warrant Shares, the parties are surely anticipating growth. This committed financing will help accelerate the development and deployment of CleanSpark's Distributed Energy Resource (DER) Solutions to commercial customers.
CLSK has outlined several initiatives in their recent letter to shareholders. CLSK is planning to initiate a marketing campaign to start reaching indoor cannabis growers dealing with inefficient energy usage in need of their services, push forward their projects with recent acquisition of Intellectual Property of Pioneer Critical Power Inc, and facilitate growth in their R&D to find new industries their solution can improve. CleanSpark's microgrid energy solution dramatically decreases the cost of energy associated with producing each pound of final product. A cannabis business using $90,000 per year in energy has the potential to reduce its operating costs (flowering stage) from $270/lb. to $200/lb., producing a 15% ROI over 10 years. Start your research now.
Today we are highlighting: CleanSpark, Inc. (USOTC: CLSK), Ballard Power Systems (NASDAQ: BLDP), Plug Power Inc. (NASDAQ: PLUG), Capstone Turbine Corporation (CPST), and ALLETE, Inc. (NYSE: ALE).
This financing is the latest in a long string of positive announcements by CleanSpark, Inc. (USOTC: CLSK) (Market Cap: $129.823M, Share Price: $2.858). The company engaged a firm to navigate their up listing, announced the near completion of a $900k contract to install a CLSK microgrid at a U.S. Marine Corps Base and has been progressing on a $18.3 million deal with NYSE company, MAC. Continue reading to learn why now is the time to start your research on CLSK. It had recently announced that it has delivered approximately $357,000 in custom electrical equipment to customers and received new orders of approximately $438,000 since the closing of the definitive agreement on January 22, 2019 to acquire the intellectual property of Pioneer Critical Power Inc. The custom equipment backlog has increased to approximately $3.9 million, an increase of approximately 8.3% from the backlog levels on the date of acquisition. Their acquisition of intellectual property of Pioneer Critical Power Inc. has already been a boon for their bottom line.
https://ih.advfn.com/stock-market/USOTC/cleanspark-inc-CLSK/stock-news/79758122/cleantech-opportunities-you-cant-miss
$CLSK $2.75
Study reveals large molecular differences between stem cells grown on different bio materials
https://medicalxpress.com/news/2019-04-reveals-large-molecular-differences-stem.html
OTC Markets- Spindle, Inc.
https://www.otcmarkets.com/stock/SPDL/overview
$CLSK website has a new look
https://cleanspark.com/
Nice run today.. $AXSM
Stuck in the mud (.86- .90 range) for a month..
This could have the same results as your MID-JUNE call from last year.. $CELZ
BREAKTHROUGH Two-year-old boy ‘cured’ of rare disease with pioneering stem cell treatment after being given weeks to live
https://www.thesun.co.uk/fabulous/8913094/boy-cured-rare-disease-stem-cell-treatment/
Factors behind embryonic stem cell state
https://www.sciencedaily.com/releases/2019/04/190417115103.htm
Global $15.63Bn Stem Cell Market by Product, Application, Technology, Therapy, and Region - Forecast to 2025 - ResearchAndMarkets.com
https://www.businesswire.com/news/home/20190418005442/en/Global-15.63Bn-Stem-Cell-Market-Product-Application
‘Super-Hero’ Stem Cells Survive Radiation to Regrow Muscles
https://www.ucsf.edu/news/2019/04/414256/super-hero-stem-cells-survive-radiation-regrow-muscles
Thank you for keeping us informed.. $USRM
Under Chapter 7, the company stops all operations and goes completely out of business. A trustee is appointed to "liquidate" (sell) the company's assets and the money is used to pay off the debt, which may include debts to creditors and investors.
https://www.sec.gov/reportspubs/investor-publications/investorpubsbankrupthtm.html
Biotricity gives doctors every financial incentive to use its devices. Biotricity charges no upfront costs. Thus doctors should have no resistance to adopting the use of Bioflux in their practice. Biotricity will use a billing model similar to Comcast in which the company initially provides users the equipment at no cost and recoups the cost through monthly fees.
Three hours and no trades, somethings up..$BTCY 0.89.. Volume (0)..
$10,750,000 Senior Secured Redeemable Convertible Promissory Note
2,150 Shares of Series B Preferred Stock
Common Stock Purchase Warrant to Purchase up to 2,300,000 Shares of Common Stock
Shares of Common Stock Issuable Upon Conversion of the Senior Secured Redeemable Convertible Promissory Note
Shares of Common Stock Issuable Upon Conversion of the Series B Preferred Stock
Shares of Common Stock Issuable Upon Exercise of the Warrant
1,250,000 Shares of Common Stock
We are offering a $10,750,000 face value Senior Secured Redeemable Convertible Promissory Note (the “Debenture”) with a 7.5% original issue discount, 2,150 shares of our Series B Preferred Stock with a 7.5% original issue discount, a Common Stock Purchase Warrant (the “Warrant”) on a cash-only basis to acquire up to 2,300,000 shares (the “Warrant Shares”) of our common stock (our “Common Stock”), the shares of our Common Stock underlying the Debenture, the shares of Common Stock underlying the Series B Preferred Stock, the Warrant Shares and 1,250,000 shares of Common Stock. The aggregate purchase price for the Debenture, the Series B Preferred Stock the Warrant and the Common Stock is $20,000,000.
The Debenture has a maturity date two years from the issuance date and we have agreed to pay compounded interest on the unpaid principal balance of the Debenture at the rate equal to 7.5% per annum. Interest is payable on the date the applicable principal is converted or on maturity. The interest must be paid in cash and, in certain circumstances, may be paid in shares of our Common Stock. The Series B Preferred Stock may convert into Common Stock and has other features as discussed elsewhere in this Prospectus. The Warrant is exercisable for a term of three years on a cash-only basis at an exercise price of $3.50 per share with respect to 2,000,000 Warrant Shares, $4.00 with respect to 100,000 Warrant Shares, $5.00 with respect to 100,000 Warrant Shares, $7.50 with respect to 50,000 Warrant Shares and $10.00 with respect to 50,000 Warrant Shares.
Prior to the maturity date, provided that no trigger event has occurred, we will have the right at any time upon 30 trading days’ prior written notice, in our sole and absolute discretion, to redeem all or any portion of the Debenture then outstanding by paying the holder an amount equal to 145% of the face value of the Debenture.
The holder may convert the Debenture into shares of our Common Stock at a conversion price equal to 90% of the mathematical average of the 5 lowest individual daily volume weighted average prices of our Common Stock, less $0.075 per share, during the period beginning on the issuance date and ending on the maturity date. No conversion is permitted at a price below $1.00 per share until approval of certain corporate actions by the shareholders is obtained and then at $0.35 per share. In the event certain equity conditions exist, we may require that the holder convert the Debenture. In no event shall the holder of the Debenture be allowed to effect a conversion if such conversion, along with all other shares of our Common Stock beneficially owned by the holder and its affiliates would exceed 4.99% of the outstanding shares of our Common Stock.
We do not intend to apply to list the Debenture, the Series Preferred Stock or Warrant on any national securities exchange or any automated dealer quotation system. Our Common Stock is listed on the OTCQB marketplace under the symbol “CLSK.” On April 16, 2019, the last reported sale price of our Common Stock was $3.34 per share.
We intend to use the net proceeds received from the sale of the above securities for general corporate purposes and the repayment of certain outstanding debt. We will not receive any additional proceeds if and when the Debenture or Series B Preferred Stock is converted, in whole or in part, into shares of our Common Stock. We will, however, receive any additional proceeds if and when the Warrant is exercised into shares of our Common Stock.
Our business and an investment in our Common Stock involve significant risks. These risks are described under the caption “Risk Factors” beginning on page S-3 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
The date on this prospectus supplement is April 17, 2019
https://ih.advfn.com/stock-market/USOTC/cleanspark-inc-CLSK/stock-news/79718906/prospectus-filed-pursuant-to-rule-424b5-424b5
Stem Cell Research & Therapy
https://stemcellres.biomedcentral.com/articles
How organs form helps stem cell researchers in their quest to develop future treatments of diabetes and cancer
https://medicalxpress.com/news/2019-03-stem-cell-quest-future-treatments.html
Stem Cell Procedure Offering Hope Of Breakthrough Cure For Crohn’s Disease
https://www.msn.com/en-us/health/medical/stem-cell-procedure-offering-hope-of-breakthrough-against-crohn’s-disease/ar-BBW0DT2
Metabolites can regulate stem cell behavior through the STAT3/AKT pathway in a similar trend to that under hypoxic conditions
Stem Cell Therapy for Thyroid Issues: A New Frontier
Discovery of 'kingpin' stem cell may help in the understanding of cancerous tumors
https://www.sciencedaily.com/releases/2019/04/190411115231.htm
Stem cells could be the answer to eliminating cancer.. $USRM
Researcher reports skin properties that may limit cancer and aid stem cell regeneration
https://medicalxpress.com/news/2019-04-skin-properties-limit-cancer-aid.html
The future is now for Stem cells.. $USRM
Good DD.. Thank you.. $USRM
$BTCY 0.90.. Volume 3,500 @ 3:10..
Call the Transfer Agent.. Continental Stock Transfer & Trust Company.. 212-509-4000 for an update on $USRM shareholders.
https://www.continentalstock.com/
https://www.otcmarkets.com/stock/USRM/security
Outstanding Shares 31,048,555 04/08/2019 +459,115
Restricted 18,231,239 04/08/2019 (0)
Unrestricted 12,817,316 04/08/2019 (0)
Thank you.. $USRM
I agreed.. Case Dismissed.. $USRM
ISAAC J. MITRANI is the managing director of Mitrani, Rynor, Adamsky & Toland, P.A., an eighteen-lawyer law firm with offices in Miami-Dade and Broward Counties.. He is a past-president of the Federal Bar Association (South Florida Chapter),
http://www.mitrani.com/attorneys/isaac-j-mitrani/
FDA thought they had an easy case.. They picked the wrong woman to mess with.. Case Dismissed.. $USRM